PARP inhibitors and maintenance treatment of recurrent platinum-sensitive ovarian cancer

Article

“The ARIEL3, NOVA, and SOLO-2 trials have definitely changed how we practice and treat patients with ovarian cancer," said Dr. Jackson.

The addition of PARP inhibitors, such as olaparib and niraparib, to the maintenance treatment of patients with recurrent, platinum-sensitive ovarian cancer has led to significant progression-free survival (PFS), according to Amanda L. Jackson, MD. THE PFS benefit with these agents were demonstrated in the phase 2 SOLO-2, NOVA, and ARIEL3 trials, respectively.

“The ARIEL3, NOVA, and SOLO-2 trials have definitely changed how we practice and treat patients with ovarian cancer. We know that there is a role for PARP maintenance [in these patients], because it seems to increase the time until they recur,” said Jackson. “In the frontline setting, hopefully, [PARP maintenance will] push even more patients into permanent remission. These studies help us see that all our patients benefit from a PARP inhibitor. It's just figuring out what's the best time to give it to them.”

To learn more about the impressive results and findings, visit OncLive.

Recent Videos
Dr. Somi Javaid highlights disparities in sexual health | Image Credit: hermd.com.
How advancements in IVF are impacting embryologist workload and patient care | Image Credit: fertility.coopersurgical.com/our_experts
Study finds no causal link between maternal health in pregnancy and autism risk | Image Credit: med.nyu.edu/faculty.
Mirvie's RNA platform revolutionizes detection of fetal growth restriction | Image Credit: wexnermedical.osu.edu
How early genetic testing empowers parents and improves outcomes | Image Credit: tuftsmedicine.org
Dallas Reed highlights trends and barriers in prenatal genetic testing | Image Credit: tuftsmedicine.org
How maternal fetal medicine specialists improve outcomes for high-risk pregnancies | Image Credit: profiles.mountsinai.org
How the cobas liat assay panels improve STI detection | Image Credit: labqualityconfab.
Screening-to-diagnosis interval vital for gestational diabetes outcomes | Image Credit: ultracon2024.eventscribe.net
Henri M. Rosenberg, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.